<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04212195</url>
  </required_header>
  <id_info>
    <org_study_id>18/0200</org_study_id>
    <nct_id>NCT04212195</nct_id>
  </id_info>
  <brief_title>Cohort Research on Wilson's Disease</brief_title>
  <acronym>CROWD</acronym>
  <official_title>Cohort Research On Wilson's Disease: Genetic Determinants and Biomarker Discovery for Neurological Involvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Wilson's disease (WD) is an inherited disorder that causes abnormal copper accumulation in
      the brain and/or liver. Some people develop neurological or psychiatric symptoms whereas
      other develop liver disease. The reasons for this are unclear but genetic factors are likely
      to contribute. Current treatment, using copper-binding medications, is required lifelong.
      Some respond well but others suffer debilitating side-effects or deteriorate despite
      treatment, leading to disability or the need for liver transplantation.

      In the first part of this study the main aim is to identify genetic factors that determine
      whether someone with a diagnosis of WD will develop neurological involvement or not. The
      investigators will invite 500 adults with WD across the UK to take part. Participants will be
      asked to complete an online questionnaire and provide a saliva sample for genetic testing
      using a collection kit sent via post. Identifying these genetic factors would significantly
      advance our understanding of the disease and may provide new targets for drug discovery or
      help guide more personalised approaches to treatment.

      In the second part of this study the main aim is to develop new ways to monitor the effect of
      WD on the brain using tests. Copper levels in blood and urine, currently used to monitor the
      disease, are unreliable and do not necessarily reflect ongoing brain damage. The role of MRI
      scans, cerebrospinal fluid tests or other measures of brain damage, commonly used in other
      neurological disorders, is unclear. The investigators will therefore follow a group of 40
      patients using clinical assessments and a combination of neurological tests, including novel
      imaging and laboratory techniques, over 24 months. Developing new approaches to monitoring
      the effect of WD on the brain will enable better prevention of neurological disability and be
      essential for demonstrating the effectiveness of new treatments, such as gene therapy, in
      clinical trials in the future.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2018</start_date>
  <completion_date type="Anticipated">December 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 6, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical phenotype</measure>
    <time_frame>Questionnaire responses will be collected over two years.</time_frame>
    <description>Responses to online questionnaires for the first part of the study will be used to the determine the presence or absence of neurological symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unified Wilson's Disease Rating Scale (UWDRS)</measure>
    <time_frame>This assessment will be performed at two research visits 12-18 months apart.</time_frame>
    <description>Participants in the second part of the study will be assessed at research visits using this scale (0-320)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Wilson's Disease</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <description>Genetic determinants (n=500)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <description>Biomarker discovery (n=40)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Next generation sequencing</intervention_name>
    <description>Saliva samples</description>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Imaging and fluid biomarkers</intervention_name>
    <description>Magnetic resonance imaging of the brain and urine, blood and cerebrospinal fluid sampling</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva (part 1). Urine, blood and, in a subset, cerebrospinal fluid (part 2).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Secondary care
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (part 1 and part 2):

          -  Diagnosed with Wilson's disease

          -  Age 16 years or over

          -  Living in the UK

        Exclusion Criteria (part 2):

          -  Participant has another medical or psychiatric illness that would interfere in
             completing assessments

          -  Participant is pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Warner</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL Queen Square Institute of Neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuel Shribman</last_name>
    <phone>02076794025</phone>
    <email>s.shribman@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Birmingham Women's and Children's NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Nicholl</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Griffiths</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiff and Vale University Health Board</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Peall</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Bomford</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital for Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Warner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanouil Tsochatzis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harpreet Dhaliwal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Masson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Ealing</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Bandmann</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genetic modifiers</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatolenticular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

